Embed Size (px)
Citation preview
PROSPECTIVE MODELS OF VACCINE SECURITY COLLABORATIONS IN RESEARCH
AND DEVELOPMENT (R&D)
DR. MARIA RUTH B. PINEDA‐CORTELASEAN – U.S. S&T Fellow on Health
Department of Science and TechnologyPhilippine Council for Health Research & Development
stablished in 2009
DrugsDiagnostics
VaccinesTraditional medicine
ASEAN Integration
2015
pproved by the ASEAN Sub-Committee n Biotechnology (SCB) and the ASEAN ommittee on Science and Technology COST)
SEAN – NDI Operations
ASEAN-NDI Secretariat
(Philippines)
CBID
LA
MY
MMPH
SG
TH
VN
BN
VISION
Asia’s premierfacilitator foresearch anddevelopmeninnovations in
health produc
build a harmonious and sustainable partnership among ASEAN untries
To ensure that health technology development and the capabmember states are maximized according to regional health ne
contribute to the “ASEAN Community 2015” thru health R&D operation
Why establish
Communicable and non-communicable
diseases
ResearchProduct Discovery
WHO Global Strategy
?
ilitate ASEAN-wide R and D collaborations
ow can ASEAN-NDI address these problems?
Capacity development requirement
Substantial and diverse human
resource
Research gap
Same diseases: same products
R & D Investment ga
Collaboration with
pharmaceutical industries
ASEAN-NDI
SEAN – NDI HIGHLIGHTS
SCB
and
COST
App
rova
l
Colla
bora
tion
with
WHO
-TDR
ASEA
N-N
DI T
ask
Forc
e
Map
ping
Sur
vey
Stra
tegi
c Bu
sines
s Pla
n (S
BP)
ASEA
N-N
DI S
ecre
taria
t -Ph
ilipp
ines
Com
mun
ity o
f Pra
ctic
e M
eetin
g on
Tr
aditi
onal
Med
icin
e
ASEA
N-N
DI A
rtic
le P
ublic
atio
n
ASEA
N-N
DIN
ewsl
ette
r
009 2011
2010
20102013
2013
2014 2014
201
Community of Practice Meeting on Traditional Medicine
June 2014 Dusit Thani Hotel Makati City, Philippines
R&D Proposal created: TM Database
9 out of the 10 ASEAN countries
Needs identified
blogs.usembassy.gov/asean/innovasean_20140929/
ewsletters and Publication
Our website:www.asean-ndi.org
ticle contributors/writers are welcome!
pping Survey Results
DRUG DEVELOPMENTTY Drug
DevelopmentTarget
Discovery Screening Product Development Clinical Trials Manufacturi
N - -B 20 10 2 10D 40 22 23 14 18 9A 3 -
MY 33 10 6 7 3 1M 19 14 3 2H 19 6 6 3 9 2G 6 6 4 1H 90 59 12 27N 18 4 6 6 12
pping Survey Results
TRADITIONAL MEDICINE DEVELOPMENTTY Trad. Med.
DevelopmentTarget
Discovery Screening Product Development Clinical Trials Manufacturi
NB 2D 16 7 2A
MY 188 8 5 6 2 1MH 16 12 14 8 4 3GH 4 2 2N 12 5 6 5 3 7
pping Survey Results
DIAGNOSTICS DEVELOPMENTTY Diagnostics
DevelopmentTarget
Discovery Screening Product Development Clinical Trials Manufacturi
N - - - - - -B 4 - - 1 2 -D 21 16 1 4 - 2A - - - - - -
MY 50 15 12 11 6 -M 2 - - - 1 -H 13 11 - 8 6 2G 5 5 4 - - -H 31 6 8 3 - -N 7 4 5 4 1 2
pping Survey Results
VACCINES DEVELOPMENTTY Vaccines
DevelopmentTarget
Discovery Screening Product Development Clinical Trials Manufacturi
N - - - - - -B 14 8 1 - - -D 12 2 - 7 2 2A - - - - - -
MY 9 4 - 2 2 -M 9 1 8 - - -H 12 6 1 1 5 1G 4 4 4 - - -H 21 12 4 2 - -N 6 - - - - 5
Current Status of Vaccines Innovation in ASEAN
Bruckler, Asia Pacific Operations, Deallus Group, 2013
ASEAN based vaccines manufacturersCountries Manufacturer Domestic production capabilities
Indonesia Bio Farma Polio (OPV) – Measles – BCGDTP –DT- TTDTP – HepB – HepB (FF)Flu (egg)
Thailand GPO-Merieux MeaslesJEV (FF)
QSMI BCG – Rabies
Viet Nam Vabiotech HepB – HepACholera – JEV – Flu (cell)
Polyvac Polio (OPV / IPV)MeaslesRotavirus
IVAC DTP – BCGRabies – Typhoid – Flu (egg)
SELECTED DISEASES TARGETED BY VACCINE R&D IN ASEAN
DiseasesCOUNTRIES
BN CB ID LA MY MM PH SG TH VN
ngue - ✓ - ✓ ✓ ✓ ✓
- ✓ - ✓ ✓ ✓ ✓
uenza - ✓ ✓ - ✓
anese ephalitis
- ✓ - ✓ ✓ ✓
rosy - ✓ - ✓ ✓
tospirosis - ✓ ✓ - ✓ ✓
aria - ✓ - ✓ ✓ ✓
ies - ✓ ✓ - ✓ ✓ ✓
erculosis - ✓ - ✓ ✓ ✓ ✓
al Infection - ✓ - ✓ ✓ ✓
o information available; Based on country reports; Elsevier, 2010
CommunicateShareUpdate
www.asean-ndi.org
Community of Practice WORKSHOP:Drugs
Diagnostics October 2015Vaccines
Email: [email protected] or [email protected]
What to expect in the upcoming Workshop on Vaccine development?
Presentation of updated country status reports
xperts on Vaccine development will be invited
Needs Assessment and Evaluation
October 201
Writing of Research and Development Proposal on Vaccine Development
ASEAN region holds a lot of potential in resources for drugsvaccines, diagnostics and traditional medicine research
development.
Work as SIMILAR INITIATIVESDIFFERENT STAGES OF ECONOMIC ANDHEALTH DEVELOPMENT
hrough ASEAN - NDI
Research and Development Collaborations on Vaccine Security
serving as a VENUE and a PLATFORM
to LINK ASEAN-member states
Thank you very much!
